Evommune drops eczema drug after trial miss
Evommune abandoned its experimental eczema treatment after it failed to meet the primary goal in a mid-stage trial. The setback sent the company shares down 24 percent in aftermarket trading. The firm plans to focus development of the drug on migraine prevention instead.
Insights:
Evommune dropped its experimental eczema drug on Tuesday after a mid-stage trial missed its main goal, sending shares down 24% in aftermarket trading. The setback halts the program for atopic dermatitis after a 12-week treatment period across 121 adult patients. The company now shifts its focus toward migraine prevention for the compound.
